Phaseline

Targets › GRIN1

GRIN1 (Glutamate receptor ionotropic, NMDA 1): drug programs, companies and trials

71 programs from 65 companies in 143 trials: 59 Phase 2, 30 Phase 1, 30 Phase 4, 24 Phase 3; Psychiatry, Neurology, Other; next expected readout Nov 2026.

Component of N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with high calcium permeability and voltage-dependent block by Mg(2+). NMDARs participate in synaptic plasticity for learning and memory formation by contributing to the long-term potentiation (LTP). (UniProt, Q05586)

Open in Phaseline: the race on GRIN1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Stanford UniversityKetamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Chronic Pain; Obsessive-Compulsive Disorder; Epilepsy; Psychiatric DisorderNov 2026
University of Puerto RicoEsketamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Treatment-resistant Depression (TRD)Dec 2026
National Institute on Alcohol Abuse and Alcoholism (NIAAA)Acamprosate calcium
Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Alcohol Use DisorderDec 2026
University of OklahomaKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Laceration of Skin; HemorrhoidsJan 2027
Peking University First HospitalIntranasal dexmedetomidine-esketamine
Combination of alpha-2 adrenergic agonist and NMDA receptor antagonist
ADRA2A, NMDAR, ADRA2B, ADRA2C, GRIN1Phase 4Adenotonsillectomy; General AnesthesiaFeb 2027
Ain Shams UniversityKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Intraoperative Awareness; Perioperative Analgesia; Sedation and Analgesia; Inhalation AnesthesiaFeb 2027
Margaux M. Salas, PhDKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Neuropathic PainMay 2027
Universidad de AntioquiaKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Pain, PostoperativeJun 2027
Icahn School of Medicine at Mount SinaiKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Major Depressive Disorder; DepressionAug 2027
Massachusetts General HospitalKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 4Major Depressive Disorder; DepressionJun 2030
Iuliu Hatieganu University of Medicine and PharmacyNefopam
Non-opioid analgesic; mechanism includes monoamine reuptake inhibition and NMDA receptor a
SLC6A2, SLC6A3, GRIN1Phase 4Pancreatoduodenectomy–
GRIN TherapeuticsRadiprodil
Glutamate NMDA receptor; GRIN1/GRIN2B antagonist
GRIN1, GRIN2BPhase 3GRIN-related Neurodevelopmental Disorder; Healthy Adult Participants; GRIN-related Disorders; Hepatic Impairment …Nov 2026
Cairo UniversityKetodex
NMDA receptor antagonist (ketamine) combined with alpha-2 adrenergic receptor agonist (dex
GRIN1, ADRA2APhase 3Postoperative Delirium (POD)Dec 2026
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sNitrous oxide
N-methyl-D-aspartate (NMDA) receptor antagonist
GRIN1Phase 3Laceration of SkinDec 2026
University Health Network, TorontoKetamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Chronic Daily Headache; Major Depressive DisorderFeb 2027
Nantes University HospitalKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Rapid Sequence InductionApr 2027
Canadian Cancer Trials GroupMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Brain MetastasesJun 2027
State University of New York at BuffaloKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Distal Radius Fracture ReductionAug 2027
Children's Oncology GroupMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Central Nervous System CarcinomaSep 2027
Assistance Publique - Hôpitaux de ParisKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Major Depressive Episode; Limb InjuryFeb 2028
Meyer Children's Hospital IRCCSL-serine
Amino acid supplementation to support GRIN-related neurodevelopmental disorders caused by
GRIN1, GRIN2A, GRIN2B, GRIN2DPhase 3GRIN-related DisordersJun 2028
Dr. Inge WinterEsketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Major Depressive DisorderJun 2028
Johnson & Johnson (Janssen)Esketamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Depressive Disorder, Treatment-Resistant; Depressive Disorder, Major; Sleep Wake Disorders; Prenatal Depression …Dec 2028
Yale Universityketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Depression; Parkinson's Disease; Posttraumatic Stress Disorder; Depressive Disorder, MajorJan 2029
University of MinnesotaD-serine
NMDA receptor co-agonist; provides glycine site modulation at NMDA receptors
GRIN1Phase 3PsychosisApr 2030
Tata Memorial CentreMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Neurocognitive DysfunctionJan 2031
NRG OncologyMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Metastatic Lung Small Cell CarcinomaJul 2031
Reinier de Graaf GroepEsketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Endometriosis–
NYU Langone HealthKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 3Chronic Postsurgical Pain–
China Medical University HospitalS1RA plus NMDAE
Sigma-1 receptor agonist plus NMDA receptor enhancer
GRIN1Phase 2Major Depressive Disorder; Schizophrenia; Prodromal Schizophrenia; Bipolar I DisorderNov 2026
Mclean HospitalCycloserine
D-alanylalanine synthetase inhibitor; Alanine racemase inhibitor
GRIN1Phase 2Depression; Borderline Personality Disorder (BPD); Major DepressionDec 2026
Naveen PoonaiIN Ketodex (D4K2)
Dexmedetomidine (alpha-2 adrenergic agonist) + Ketamine (NMDA receptor antagonist)
ADRA2A, GRIN1Phase 2FractureDec 2026
Dr. med. Marcus HerdenerKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Cocaine Use Disorder; Alcohol Abuse/DependenceDec 2026
University of VirginiaMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Alzheimer DiseaseDec 2026
The University of Texas Health Science Center at San AntonioKetamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Suicide; Suicidal IdeationDec 2026
National Institute of Mental Health (NIMH)Ketamine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Healthy Volunteers; Healthy Volunteer; DepressionJan 2027
Case Comprehensive Cancer CenterMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Brain MetastasesMay 2027
University of ChicagoMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Skin-PickingJun 2027
Shanghai Mental Health CenterMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Obsessive-Compulsive DisorderJun 2027
National Institute of Mental Health (NIMH)(2R,6R)-hydroxynorketamine
Enhancer of synaptic glutamate release
GRIN1, GRIN2Phase 2SuicideJul 2027
Christian Hassageresketamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Out-of-hospital Cardiac Arrest (OHCA)Sep 2027
Syndeio BiosciencesZelquistinel
Positive allosteric modulator of the N-Methyl-D-Aspartate (NMDA) receptor
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2DPhase 2Major Depressive Disorder; Healthy Volunteers in Fed and Fasted StateSep 2027
Stanford UniversityNitrous Oxide
NMDA receptor antagonist
GRIN1Phase 2Obsessive-Compulsive DisorderOct 2027
Arialys AustraliaART5803
Monovalent antibody that binds to the NTD of NMDAR NR1 subunit and blocks pathogenic anti-
GRIN1Phase 2Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE)Nov 2027
University of PennsylvaniaAmantadine
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Stroke, IschemicDec 2027
Haukeland University HospitalD-serine
NMDAR co-agonist; modulates N-methyl-D-aspartate receptor function
GRIN1, GRIN2A, GRIN2BPhase 2Parkinson s DiseaseMar 2028
Medical College of WisconsinMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Brain MetastasesMay 2028
Inova Health Care ServicesMemantine Hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Hepatocellular CarcinomaJul 2028
University of Maryland, BaltimoreKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Opioid Use DisorderAug 2028
VA Office of Research and DevelopmentKetamine hydrochloride
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Chronic Low Back Pain; Parkinson's DiseaseDec 2028
UNC Lineberger Comprehensive Cancer CenterMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Breast CancerJun 2029
Samer GawriehAcamprosate
Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Alcohol-associated HepatitisDec 2029
The University of Texas Health Science Center at San AntonioMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Brain TumorJul 2030
University of EdinburghAmantadine
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Motor Neuron Disease, Amyotrophic Lateral SclerosisDec 2030
SHINKEI TherapeuticsAmantadine Hydrochloride (MR-301)
Glutamate [NMDA] receptor antagonist; Matrix protein 2 inhibitor
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Traumatic Brain Injury–
New York State Psychiatric InstituteCI-581a
NMDA receptor antagonist (ketamine analog)
GRIN1Phase 2Alcohol Use Disorder; Post-acute Sequelae of COVID-19–
New York State Psychiatric InstituteCI-581b
NMDA receptor antagonist (ketamine analog)
GRIN1Phase 2Alcohol Use Disorder; Post-acute Sequelae of COVID-19–
Sohag UniversityKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Generalized Convulsive Status Epilepticus; Convulsive Status EPILEPTICUS–
Children's Hospital Medical Center, CincinnatiMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 2Fragile X Syndrome–
The AlfredNMDA receptor antagonist
NMDA receptor antagonist
GRIN1, GRIN2A, GRIN2B, GRIN2C, GRIN2DPhase 2Borderline Personality Disorder–
AptinyxNYX-458
NMDAR modulator
GRIN1, GRIN2A, GRIN2BPhase 2Mild Cognitive Impairment–
atai TherapeuticsVLS-01 buccal film
N-methyl-D-aspartate (NMDA) receptor antagonist
GRIN1Phase 2Treatment Resistant Depression–
Yale UniversityEthanol
GABA-A receptor potentiator and NMDA receptor antagonist
GABRA1, GRIN1Phase 1CannabisDec 2026
University of ZurichMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1GlioblastomaDec 2026
Mclean HospitalD-serine
NMDA receptor co-agonist
GRIN1Phase 1DepressionDec 2026
Bjorn H. EbdrupMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1PsychosisDec 2026
Rush University Medical Center(2R,6R)-Hydroxynorketamine
NMDA receptor antagonist (active metabolite of ketamine)
GRIN1Phase 1Pain, NeuropathicApr 2027
Washington University School of MedicineNitrous Oxide
NMDA receptor antagonist
GRIN1, GRIN2A, GRIN2BPhase 1Depressive Disorder, MajorApr 2027
Jeffrey MillerMemantine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1Major Depressive Disorder (MDD)Jun 2027
National Institute of Neurological Disorders and Stroke (NINDS)Acamprosate calcium
Glutamate [NMDA] receptor antagonist; GABA-A receptor; anion channel positive modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1Amyotrophic Lateral SclerosisSep 2027
University of UtahKetamine
Glutamate [NMDA] receptor negative allosteric modulator
GRIN1, GRIN2A, GRIN2B, GRIN2D, GRIN3BPhase 1Opioid-use Disorder; PainDec 2027

Conditions

Major Depressive Disorder (11) Depression (6) Schizophrenia (5) Cannabis (3) Alcohol Use Disorder (3) Brain Metastases (3) Depressive Disorder, Major (3) Obsessive-Compulsive Disorder (3) Fracture (3) Post-acute Sequelae of COVID-19 (2) GRIN-related Disorders (2) Suicide (2)

Modalities

small molecule (65), mixed (2), protein or peptide (1)

Companies

Yale University (2) Mclean Hospital (2) New York State Psychiatric Institute (2) National Institute of Mental Health (NIMH) (2) The University of Texas Health Science Center at San Antonio (2) Stanford University (2) The Alfred (1) Reinier de Graaf Groep (1) Christian Hassager (1) Syndeio Biosciences (1) China Medical University Hospital (1) Massachusetts General Hospital (1) Samer Gawrieh (1) Iuliu Hatieganu University of Medicine and Pharmacy (1) Children's Oncology Group (1) Tata Memorial Centre (1) University of Zurich (1) Dr. med. Marcus Herdener (1) GRIN Therapeutics (1) Medical College of Wisconsin (1)

Related targets

GRIN2B (54) GRIN2A (53) GRIN2D (50) GRIN3B (47) ADRA2A (3) GRIN2C (2) GABRA1 (1) SLC6A2 (1) SLC6A3 (1) GRIN2 (1) NMDAR (1) ADRA2B (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.